PCVX Vaxcyte, Inc.

NEUTRAL Impact: 3/10 DEFA14A
Horizon weeks Filed Apr 23, 2026 Processed 1mo ago SEC 0001193125-26-173686
Proxy solicitation materials
Latest settled — T+20d
PCVX ▼ -20.34% at T+20d
NEUTRAL call ✗ call lost -20.34% · α vs SPY -24.37% · entry $59.49 → $47.39
Next anchor: T+60d in 6w
Last close $46.33 (close Jun 8) · -22.12% from $59.49 entry
Entry anchored
Apr 23, 03:59 PM ET
via Databento tick
T+1d
+0.39%
call +0.39% · α +0.22%
$59.72
settled 7w ago
T+5d
-3.78%
call -3.78% · α -4.69%
$57.24
settled 6w ago
T+20d
-20.34%
call -20.34% · α -24.37%
$47.39
settled 20d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

Vaxcyte, Inc. (PCVX) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, scheduled for June 15, 2026. The meeting will vote on the election of three Class III directors, the ratification of Deloitte & Touche LLP as the independent auditor, and the approval of executive compensation. The filing is routine and does not contain any material financial data or significant corporate actions.

Actionable Insight

Monitor the company's next 10-Q filing for any updates on financial performance or guidance, as this proxy statement contains no new financial information.

Key Facts

  • The filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting.
  • The meeting will be held on June 15, 2026.
  • Proposals include the election of three Class III directors: Olivier Brandicourt, Halley Gilbert, and Grant E. Pickering.
  • The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 will be ratified.
  • The compensation of the named executive officers will be approved on an advisory basis.
  • The Board recommends voting 'For' on all proposals.
  • The filing is routine and does not contain any material financial data or significant corporate actions.

Financial Impact

No material financial impact. The filing is a routine administrative document.

Risk Factors

  • The lack of new financial information or strategic updates in the filing means investors must wait for the next quarterly report for material updates.
  • The advisory vote on executive compensation could be a point of contention for shareholders, although it is non-binding.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-173686
Document: 0001193125-26-173686-index-headers.html0001193125-26-173686
Document: 0001193125-26-173686-index.html0001193125-26-173686
Document: 0001193125-26-173686.txt0001193125-26-173686
7 reports for PCVX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PCVX — sortable, filterable
Type Now
Jun 2, 2026
7d ago
Press Release
NEUTRAL ★ 4/10
$46.93 $48.76▲ +3.90%▲ +3.49%$46.33 (−1.28%)
May 6, 2026
4w ago
8-K
BEARISH ★ 7/10
$51.48 $53.01▼ −2.97%▼ −2.14%$46.33 (+10.00%)
Apr 23, 2026
6w ago
DEFA14A
NEUTRAL ★ 3/10
$59.49 $59.72▲ +0.39%▲ +0.22%$46.33 (−22.12%)
Apr 1, 2026
10w ago
Insider Cluster
NEUTRAL ★ 3/10
$58.50 $58.38▼ −0.21%▼ −0.28%$46.33 (−20.80%)
Mar 23, 2026
11w ago
Press Release
NEUTRAL ★ 4/10
$55.94 $54.67▼ −2.27%▼ −1.91%$46.33 (−17.18%)
Feb 24, 2026
15w ago
8-K
NEUTRAL ★ 4/10
$63.04 $60.00▼ −4.82%▼ −4.28%$46.33 (−26.51%)
Feb 24, 2026
15w ago
8-K
NEUTRAL ★ 5/10
$63.04 $60.00▼ −4.82%▼ −4.28%$46.33 (−26.51%)
Showing 7 of 7

US Market Status

Market Closed — Opens in 6h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access